Alumis Inc.
ALMS · NASDAQ
Company research
Alumis Inc. (Nasdaq: ALMS) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing next-generation precision oral therapies for immune-mediated and autoimmune disorders. The company's lead pipeline asset, envudeucitinib (formerly ESK-001), is an allosteric tyrosine kinase 2 (TYK2) inhibitor currently being evaluated in late-stage clinical trials for the treatment of moderate-to-severe plaque psoriasis and systemic lupus erythematosus, while its second candidate, A-005, is a CNS-penetrant TYK2 inhibitor in Phase 1 development targeting neuroinflammatory and neurodegenerative diseases such as multiple sclerosis. Alumis also advances lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease, and leverages a proprietary data analytics platform to drive its precision immunology approach. Founded in 2021 and formerly known as Esker Therapeutics, Inc., the company completed its IPO on the NASDAQ in June 2024 and currently carries a market capitalization of approximately $3.5 billion under the leadership of CEO Martin Babler.
Research reports
Report argues Alumis is a de‑risked, pre‑commercial immunology company after best‑in‑class Phase 3 psoriasis data for envudeucitinib, with strong cash runway and upside from lupus and neuro‑immunology.
StockInvest.us · July 25, 2025Alumis Inc. Common Stock Technical Analysis (Fri, Jul 25, 2025)Technical report labels ALMS a high‑risk “buy candidate,” detailing positive moving‑average and MACD signals, support and resistance levels, volatility, and a three‑month downside price projection.